Evidence map›Paper›PMID 40302009›Full record

ArticlePerioperative medicine (London, England)2025

Effects of ciprofol on respiratory-related adverse incidence in patients with obesity during painless gastroscopy: a prospective, randomized clinical trial.

Yanjing Zhang, Danru Xie, Feifei Li, Mengjiao Che, Yaoheng Yang, Geng Li, Yiwen Zhang

Abstract read
In one paragraph

Article in Perioperative medicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yanjing Zhang *Department of Anesthesiology, Shunde Hospital of Southern Medical University (The First People's Hospital, Shunde District, Foshan City), Foshan, 528308, China.
Danru Xie *Department of Anesthesiology, Shunde Hospital of Southern Medical University (The First People's Hospital, Shunde District, Foshan City), Foshan, 528308, China.
Feifei LiDepartment of Anesthesiology, Shunde Hospital of Southern Medical University (The First People's Hospital, Shunde District, Foshan City), Foshan, 528308, China.
Mengjiao CheDepartment of Anesthesiology, Shunde Hospital of Southern Medical University (The First People's Hospital, Shunde District, Foshan City), Foshan, 528308, China.
Yaoheng YangDepartment of Anesthesiology, Shunde Hospital of Southern Medical University (The First People's Hospital, Shunde District, Foshan City), Foshan, 528308, China.
Geng LiDepartment of Anesthesiology, Shunde Hospital of Southern Medical University (The First People's Hospital, Shunde District, Foshan City), Foshan, 528308, China.
Yiwen ZhangDepartment of Anesthesiology, Shunde Hospital of Southern Medical University (The First People's Hospital, Shunde District, Foshan City), Foshan, 528308, China. ssss047@163.com.

Funding

023 Key Scientific Research Platforms and Projects of Ordinary Universities in Guangdong Province 2023ZDZX20082021 Key Specialist Project of Clinical Medicine, Shunde Hospital of Southern Medical University (Cultivation Project) SRSP20210392023 Basic and Applied Basic Research Joint Fund in Guangdong Province (Guangdong-Foshan) 2023A1515140142
6 · The paper itself

Abstract

backgroundCiprofol is an intravenous anesthetic agent which in low doses produces sedation. It was developed via structural modification of propofol. Ciprofol is claimed to reduce respiratory depression. The object of the present study was to investigate whether or not ciprofol did actually reduce respiratory depression or not in patients with obesity undergoing gastroscopy.

methodsA total of 84 patients with obesity scheduled for gastroscopy were enrolled. The participants were randomly allocated to receive sedation with ciprofol (group C) or propofol (group P). The primary outcome was the incidence of respiratory-related adverse events (AEs), whereas the secondary outcomes were the incidence of further intraoperative and postoperative AEs; procedure and anesthesia success rates; Narcotrend index (NI); induction dosage; procedure time; recovery time; discharge time; and satisfaction ratings from the patients, anesthesiologists, and endoscopists.

resultsThe incidence of respiratory-related AEs was significantly lower in group C than in group P (17.5% vs. 57.5%; P < 0.001). The occurrence of hypotension and movement during procedural events in group C was markedly reduced compared with that in group P (P = 0.024 and 0.007, respectively). No notable differences were observed in the occurrence of additional AEs or in the success rates of the procedure and anesthesia between the two groups (P > 0.05). The three-point satisfaction levels were comparable between the groups (P > 0.05).

conclusions0.4 mg/kg of ciprofol provides anesthesia comparable with 2.0 mg/kg of propofol. However, it is related to reduced respiratory-related AEs and hypotension during gastroscopy in patients with obesity; thus, ciprofol is preferred to propofol for anesthesia in obese patients.

trial registrationThis study was registered in the Chinese Clinical Trial Registry (KYLS20230625; first registration date: 29/06/2023).

Indexed as

CiprofolGastroscopyObesityRespiratory-related adverse incidence

Identifiers

PMID40302009
PMCPMC12038989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.